Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. (LH) filed a Form 144 reporting a proposed sale of 3,903 shares of common stock with an aggregate market value of $1,059,371.39. The filing lists 83,100,000 shares outstanding and names Fidelity Brokerage Services as the broker; the sale is slated for 08/13/2025 on the NYSE.
The filing shows the securities were acquired via an option granted on 02/12/2019, with acquisition and payment dated 08/13/2025, and payment made in cash. It also reports no securities sold in the past three months for the selling person and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH), reported a sale of company common stock on 08/11/2025. The Form 4 discloses that 5,643 shares were disposed of at a reported price of $266.78 per share pursuant to a plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The filing was executed by an attorney-in-fact on 08/13/2025.
After the reported transaction Schechter beneficially owns 93,319 shares directly. No derivative transactions are reported on this Form 4. The disclosure identifies the transaction code as an S-sale under the stated 10b5-1 plan.
Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.
Labcorp Holdings (LH) – insider sale by finance executive
Form 4 filed 07/31/2025 details that SVP & Chief Accounting Officer Peter J. Wilkinson sold a total of 202 common shares on 07/29/2025 in two open-market transactions: 102 shares at $261.0102 and 100 shares at $261.035. Estimated gross proceeds equal roughly $52.7 k. Following the sales, Wilkinson’s direct ownership fell to 1,852.2194 shares. No derivative securities were reported.
The activity modestly reduces the executive’s stake and is immaterial relative to Labcorp’s share count, though investors may note it when tracking insider sentiment.